Fully harnessing the power of immunotherapy through protein sequencing
Date: 29 September 2021
Time: 4:00 pm
Dating back to the third century BC in China, immunotherapy has a rich history of harnessing the power of the immune response to treat diseases. Today, immunotherapy is much more sophisticated than those initial inoculations. At the clinic, it is routinely used to fight cancer in humans and animals, as well as treating viral diseases such as Ebola. Advances in molecular biology and biochemistry – namely, developments in antibody discovery and engineering and breakthroughs in cell and gene therapy – have turned immunotherapy into a robust clinical weapon that now includes a diverse armamentarium (e.g., monoclonal antibody drugs, antibody-drug conjugates, CAR-Ts, etc).
The bottleneck threatening immunotherapy innovation
Yet, current characterisation and discovery tools lack the comprehensive insight offered by proteomics to herald in the next generation of immunotherapeutics. The latter tools do not provide insight into the structure such as PTMs, and fail to provide information on additional chains that could be present that would affect reproducibility, resulting in costly and time-consuming troubleshooting. In contrast to these tools, protein sequencing is an honest harbinger for the future of immunotherapy as it offers direct access to the end product – the protein.
The protein sequencing solution
Rapid Novor’s protein sequencing tool set includes REmAb®, and REpAb®. In this webinar, we will focus on the innovative and well established antibody monoclonal sequencing technology of REmAb®, which laid the strong foundation for the development of our polyclonal sequencing technology behind REpAb®’s antibody discovery platform. With REmAb®, our clients have been able to immortalise and patent their findings, revive cell lines that otherwise would have stalled projects or discontinue products, and most importantly fully characterise their antibodies